An Open-Label, Multicenter, Dose-Escalation Phase Ib Study With Expansion Phase to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of Emactuzumab and RO7009789 Administered in Combination in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Emactuzumab (Primary) ; Selicrelumab (Primary)
- Indications Breast cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Mesothelioma; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 29 Aug 2017 Planned End Date changed from 1 Jul 2018 to 28 Jul 2018.
- 29 Aug 2017 Planned primary completion date changed from 1 Jul 2018 to 28 Jul 2018.
- 06 May 2016 New trial record